July 31, 2024
What’s up with the MOU?
With all the coverage of GLP-1s, the proposed MOU between states and FDA has faded into the background, but it’s still out there, and APC is keeping track of developments.
Find out the latest during “The MOU, 503A Adverse Events Reporting, and What’s Next” — a panel discussion that’s part of Compounders on Capitol Hill(Sept. 17–18, in case somehow you missed that). It features Congressman Morgan Griffith of Virginia, Rachel Pontikes of international law firm Reed Smith, and hopefully Ilisa Bernstein, formerly with FDA and APhA; it’s moderated by APC’s David Pore.
What’ll it cover? Well, lots:
- Will the FDA go back to the drawing board, or is a legislative fix the right move?
- What about more litigation? How will the Supreme Court’s overturning the Chevron doctrine affect this?
- What have states indicated they’ll do with a potential MOU? Which states have said they can’t or won’t sign it?
- What’s going on with Rep. Morgan Griffith’s proposed legislation that would eliminate the MOU in law?
If you want the answers to these questions, you need to register and join us in Washington, DC this September.
P.S. The sooner you register, the sooner we can get your Hill visits scheduled. That’s right — we take care of all of the logistics for you when it comes to setting up meetings with your members of Congress. But we have to know you’re coming in order to do that. So get on it.
